Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Middle East Conflict Impacts Australia and New Zealand Businesses 
SOUTH SAN FRANCISCO, Calif., April 30, 2018 -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2018, and provide a general business overview on Wednesday, May 9, 2018, at 4:30 p.m. ET (1:30 p.m. PT).
Conference Call Details
The live conference call on Wednesday, May 9, 2018, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 7068059. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact:
Cara Miller
Portola Pharmaceuticals
[email protected]
Media Contact:
Laurie Masonson
Pure Communications
[email protected]
